Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13941MR)

This product GTTS-WQ13941MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13941MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ949MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ1133MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ2889MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ123MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ2004MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGT-181
GTTS-WQ3737MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ11080MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ10707MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M-1095
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW